A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
NCT ID: NCT03114254
Last Updated: 2022-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
17 participants
INTERVENTIONAL
2014-12-05
2016-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)
NCT00058448
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
NCT02243605
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.
NCT04066595
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
NCT04122911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cabazitaxel
Six cycles of chemotherapy comprising:
Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days
Cabazitaxel
Six cycles of chemotherapy comprising:
Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabazitaxel
Six cycles of chemotherapy comprising:
Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance status ECOG 0-2
* Written informed consent
* Measurable disease as per RECIST 1.1
* Fit to receive cabazitaxel as second line chemotherapy
* Previously received TPF or cisplatin-5FU as first line systemic chemotherapy for penile cancer
* Adequate organ function as evidenced by the following peripheral blood counts and serum biochemistry at enrollment:
* Neutrophils ≥1.5 x 109/L
* Haemoglobin ≥10 g/dL
* Platelets ≥100 x 109/L
* Total bilirubin \<1.5 upper limit of normal (ULN)
* Alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤1.5 x ULN
* Serum creatinine ≤1.5 x ULN. (If creatinine is 1.0-1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with a creatinine clearance \<60 ml/min should be excluded.)
Exclusion Criteria
* Squamous carcinoma of the urethra
* T1 N1 M0 disease
* T2 N1 M0 disease
* Unfit for this regimen (as assessed by the multidisciplinary team)
* Contraindication to chemotherapy
* ECOG Performance Status \> 2
* Active Grade ≥2 peripheral neuropathy
* Active secondary cancers
* Other concurrent serious illness or medical conditions
* Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension, history of congestive heart failure, or myocardial infarction within last 6 months.
* Uncontrolled diabetes mellitus.
* History of severe hypersensitivity reaction (≥grade 3) to docetaxel
* History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs
* Active infection requiring systemic antibiotic or anti-fungal medication
* Participation in another clinical trial with any investigational drug within 30 days prior to study registration.
* Concurrent or planned treatment with strong inhibitors of cytochrome P450 3A4/5. A 1-week washout period is necessary for patients who are already on these treatments.
* Concurrent or planned treatment with strong inducers of cytochrome P450 3A4/5. A 1-week washout period is necessary for patients who are already on these treatments.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
University Hospitals Bristol and Weston NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amit Bahl
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Bristol and Weston NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bristol Haematology and Oncology Centre, Horfield Road
Bristol, , United Kingdom
Universitty College Hospitals NHS Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Seixas AL, Ornellas AA, Marota A, Wisnescky A, Campos F, de Moraes JR. Verrucous carcinoma of the penis: retrospective analysis of 32 cases. J Urol. 1994 Nov;152(5 Pt 1):1476-8; discussion 1478-9. doi: 10.1016/s0022-5347(17)32450-3.
Soria JC, Fizazi K, Piron D, Kramar A, Gerbaulet A, Haie-Meder C, Perrin JL, Court B, Wibault P, Theodore C. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol. 1997 Nov;8(11):1089-98. doi: 10.1023/a:1008248319036.
Cubilla AL, Ayala MT, Barreto JE, Bellasai JG, Noel JC. Surface adenosquamous carcinoma of the penis. A report of three cases. Am J Surg Pathol. 1996 Feb;20(2):156-60. doi: 10.1097/00000478-199602000-00003.
Somogyi L, Kalman E. Metaplastic carcinoma of the penis. J Urol. 1998 Dec;160(6 Pt 1):2152-3. doi: 10.1097/00005392-199812010-00059. No abstract available.
Tomic S, Warner TF, Messing E, Wilding G. Penile Merkel cell carcinoma. Urology. 1995 Jun;45(6):1062-5. doi: 10.1016/s0090-4295(99)80134-4.
Kim ED, Kroft S, Dalton DP. Basal cell carcinoma of the penis: case report and review of the literature. J Urol. 1994 Nov;152(5 Pt 1):1557-9. doi: 10.1016/s0022-5347(17)32471-0.
Bundrick WS, Culkin DJ, Mata JA, Gonzalez E, Zitman R, Venable DD. Penile malignant melanoma in association with squamous cell carcinoma of the penis. J Urol. 1991 Nov;146(5):1364-5. doi: 10.1016/s0022-5347(17)38096-5.
Oppenheim AR. Sebaceous carcinoma of the penis. Arch Dermatol. 1981 May;117(5):306-7. No abstract available.
Wood EW, Gardner WA Jr, Brown FM. Spindle cell squamous carcinoma of the penis. J Urol. 1972 Jun;107(6):990-1. doi: 10.1016/s0022-5347(17)61190-x. No abstract available.
Srinivas V, Morse MJ, Herr HW, Sogani PC, Whitmore WF Jr. Penile cancer: relation of extent of nodal metastasis to survival. J Urol. 1987 May;137(5):880-2. doi: 10.1016/s0022-5347(17)44281-9.
Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993 Nov;72(5 Pt 2):817-9. doi: 10.1111/j.1464-410x.1993.tb16273.x.
Slaton JW, Morgenstern N, Levy DA, Santos MW Jr, Tamboli P, Ro JY, Ayala AG, Pettaway CA. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001 Apr;165(4):1138-42.
Solsona E, Iborra I, Rubio J, Casanova JL, Ricos JV, Calabuig C. Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. J Urol. 2001 May;165(5):1506-9.
Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer. 1990 Feb 1;65(3):433-8. doi: 10.1002/1097-0142(19900201)65:33.0.co;2-g.
Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. doi: 10.1016/s0022-5347(17)37327-5.
Ahmed T, Sklaroff R, Yagoda A. Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol. 1984 Sep;132(3):465-8. doi: 10.1016/s0022-5347(17)49693-5.
Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA Jr, Costanzi JJ. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol. 1989 Jan;141(1):66-7. doi: 10.1016/s0022-5347(17)40590-8.
Sklaroff RB, Yagoda A. Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma. Cancer. 1979 Nov;44(5):1563-5. doi: 10.1002/1097-0142(197911)44:53.0.co;2-s.
Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marreaud S, Oliver RDT; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-1307. doi: 10.1093/annonc/mdn149. Epub 2008 Apr 15.
Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011 Apr;7(4):497-506. doi: 10.2217/fon.11.23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-002336-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CabazL05881
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
ON/2012/4233
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.